Takeda Pharmaceutical Co Ltd ADR TAK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
-
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
-
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
-
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
-
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
-
Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue — Update
-
Takeda Pharmaceutical Reports Rise in First-Quarter Net Profit on Higher Revenue
-
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
Trading Information
- Previous Close Price
- $14.65
- Day Range
- $14.54–14.67
- 52-Week Range
- $12.58–15.63
- Bid/Ask
- $13.95 / $14.75
- Market Cap
- $46.09 Bil
- Volume/Avg
- 1.6 Mil / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- 16.40
- Price/Sales
- 1.56
- Dividend Yield (Trailing)
- 4.20%
- Dividend Yield (Forward)
- 4.02%
- Total Yield
- 4.23%
Company Profile
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 49,281
- Website
- https://www.takeda.com
Competitors
Valuation
|
Metric
|
TAK
|
JNJ
|
4519
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.40 | 15.40 | 35.35 |
Price/Book Value | 0.94 | 5.43 | 6.89 |
Price/Sales | 1.56 | 4.58 | 11.13 |
Price/Cash Flow | 7.79 | 17.42 | 30.74 |
Price/Earnings
TAK
JNJ
4519
Financial Strength
|
Metric
|
TAK
|
JNJ
|
4519
|
|---|---|---|---|
Quick Ratio | 0.66 | 0.77 | 4.02 |
Current Ratio | 1.26 | 1.07 | 5.09 |
Interest Coverage | 1.21 | 24.45 | — |
Quick Ratio
TAK
JNJ
4519
Profitability
|
Metric
|
TAK
|
JNJ
|
4519
|
|---|---|---|---|
Return on Assets (Normalized) | 2.91% | 13.17% | 18.61% |
Return on Equity (Normalized) | 6.11% | 32.42% | 22.00% |
Return on Invested Capital (Normalized) | 4.29% | 20.93% | 21.98% |
Return on Assets
TAK
JNJ
4519
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Gkkssqxwp | Hxg | $88.3 Bil | |||
| Merck KGaA ADR
MKKGY
| Rgmwqywvk | Npbfbh | $78.0 Bil | |||
| Haleon PLC ADR
HLN
| Jqpqzld | Ldch | $48.4 Bil | |||
| Viatris Inc
VTRS
| Zpkpkzrd | Crdht | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Dbdwysdl | Sqff | $13.5 Bil | |||
| Catalent Inc
CTLT
| Bmbkyll | Kprjsq | $10.9 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Tbsbskkd | Sscrbs | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Twjwkxpdf | Zrw | $3.5 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Frcxmhjz | Mfvw | $2.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Rtqjqpkrl | Pnnm | $2.3 Bil |
United States